We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer Expands Drug Discovery Collaboration with X-Chem
Read MoreHide Full Article
Bayer AG (BAYRY - Free Report) announced that it has entered into an expanded global drug discovery deal with privately held biotechnology company, X-Chem, Inc., across multiple therapeutic areas and target classes. The collaboration focuses on the discovery of innovative lead structures for complex drug targets in areas of high unmet medical need.
The latest agreement will extend Bayer’s access to X-Chem’s DEX technology, which is based on DNA-encoded libraries of small molecules with more than 120 billion molecules.
Per the terms of the new agreement, X-Chem will receive up-front payment, research and development funding, in addition to potential pre-clinical, clinical and regulatory milestone payments, worth up to $528 million. In addition, X-Chem is eligible to receive royalties and sales milestones for each successfully commercialized drug that results from collaboration program. Moreover, Bayer will have an exclusive option to license programs generated through the collaboration.
We note that the companies have been partners under a research collaboration since 2012. Bayer has already licensed two programs for multiple series of small molecules from X-Chem that address complex target structures such as protein-protein interactions.
We are positive on the latest expansion of the existing deal. The new multi-year collaboration agreement is expected to significantly expand the scope and duration of the partnership.
Bayer is currently a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Merrimack Pharmaceuticals, Inc. , Fibrocell Science, Inc. and Bristol-Myers Squibb Co. (BMY - Free Report) . While Merrimack and Fibrocell sport a Zacks Rank #1 (Strong Buy), Bristol-Myers carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bayer Expands Drug Discovery Collaboration with X-Chem
Bayer AG (BAYRY - Free Report) announced that it has entered into an expanded global drug discovery deal with privately held biotechnology company, X-Chem, Inc., across multiple therapeutic areas and target classes. The collaboration focuses on the discovery of innovative lead structures for complex drug targets in areas of high unmet medical need.
The latest agreement will extend Bayer’s access to X-Chem’s DEX technology, which is based on DNA-encoded libraries of small molecules with more than 120 billion molecules.
Per the terms of the new agreement, X-Chem will receive up-front payment, research and development funding, in addition to potential pre-clinical, clinical and regulatory milestone payments, worth up to $528 million. In addition, X-Chem is eligible to receive royalties and sales milestones for each successfully commercialized drug that results from collaboration program. Moreover, Bayer will have an exclusive option to license programs generated through the collaboration.
BAYER A G - ADR Price
BAYER A G -ADR Price | BAYER A G -ADR Quote
We note that the companies have been partners under a research collaboration since 2012. Bayer has already licensed two programs for multiple series of small molecules from X-Chem that address complex target structures such as protein-protein interactions.
We are positive on the latest expansion of the existing deal. The new multi-year collaboration agreement is expected to significantly expand the scope and duration of the partnership.
Bayer is currently a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Merrimack Pharmaceuticals, Inc. , Fibrocell Science, Inc. and Bristol-Myers Squibb Co. (BMY - Free Report) . While Merrimack and Fibrocell sport a Zacks Rank #1 (Strong Buy), Bristol-Myers carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>